JNJBy Calypso Research7 min read

Johnson & Johnson (JNJ) Q4 2025 Earnings Analysis

A Little Band-Aid Can't Fix 9.1% Growth Concerns

Key Takeaways

Johnson & Johnson (JNJ) reported Q4 2025 earnings with revenue of $24.6B, representing a +9.1% year-over-year change. The stock moved -0.1% on earnings day.

The bull case: A diversified, increasingly high-growth portfolio in oncology, immunology, neuroscience, and medtech—backed by visible pipeline and mix upgrades—supports accelerating revenue toward double digits with steady margin expansion and multiple $5B+ assets (Tremfya, CAPLYTA, Inlexo, Milvexian) driving upside.

The bear case: Litigation overhang, policy/tariff headwinds, execution risk in medtech (EP/PFA, Ottava) and new drugs (Inlexo, Milvexian), plus ongoing LOE erosion and only modest guided margin leverage, could prevent J&J from achieving its targeted double-digit growth and constrain valuation re-rating.

Financial Highlights

  • Revenue: $24.6B (+9.1% YoY)
  • Gross Profit: $21.2B (86.4% margin, +18.0% YoY)
  • Operating Income: $5.4B (21.9% margin, +4.9% YoY)
  • Net Income: $5.1B
  • TTM Revenue: $94.2B

Stock Performance

  • Earnings Day Move: -0.1%
  • Year-to-Date: +18.6%
  • 1-Year Return: +50.1%
  • vs. S&P 500 (since earnings): +11.2%
  • vs. Nasdaq (since earnings): +12.3%

View live JNJ data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Johnson & Johnson's Q4 2025 earnings call:

Credibility of Double-Digit Revenue Growth Outlook vs. Street’s ~6% Assumptions

Sentiment: Positive

"We said 2025 would be a catapult year for Johnson & Johnson, and that is exactly what it was... And as I said before, we have line of sight to double-digit growth in the later part of the decade, which is especially remarkable for a company that, according to our guidance, would be $100 billion in sales in 2026." — Joaquin Duato
"So, you know, we have about a dozen new product launches for the company... so I would say that in that sense, it's essentially what I would call derisked, and some of you have called our story of growth in the second half of the decade as one of the cleanest stories of growth for the healthcare sector." — Joaquin Duato

MedTech Growth Durability and EP / PFA Competitiveness (Including ACA/Policy Overhang)

Sentiment: Positive

"Firstly, based on what we know today, we do not expect the loss of ACA subsidies or any potential policy changes under the big one big beautiful bill to have a material impact on our medtech performance... The primary constraint... is really more about clinical capacity, not coverage levels." — Tim Schmid
"You will have seen that in the fourth quarter, our [EP] growth accelerated to 9.5%... We're seeing this driven by the success of Verapulse, more than 40,000 cases today... and we remain resolute and confident that our deep EP expertise earned over thirty years and our robust pipeline position us well to continue to drive global leadership in this important space." — Tim Schmid

Margin Expansion Trajectory vs. Reinvestment Needs and Headwinds

Sentiment: Positive

"In 2026, we expect to drive continued operating efficiencies, the majority of which we plan to invest in our business to power our new product launches and pipeline... Despite that increased investment, we are planning for our 2026 adjusted pretax operating margin to improve by at least 50 basis points." — Joe Wolk
"I’ll harken back to our last Investor Day where we said that earnings would be commensurate with sales growth. So you can expect that the margin profile will improve in conjunction with the sales growth profile as we move out to the next couple of years and to the back half of this decade." — Joe Wolk

Portfolio Repositioning and Ortho Separation: How Far Can “High-Growth Mix” Go?

Sentiment: Positive

"If you look at the $34 billion business today, we have roughly half of our assets participating in higher growth markets growing north of 5%. That's compared to about 20% in 2018. And this will catapult to north of 70% following the ortho separation." — Tim Schmid
"Our aspiration is not to put a limit on the high-growth markets in which we participate... once we separate ortho, we'll be at least at 70%. And there is tremendous opportunity even just focused within the three business units we've decided to focus on within MedTech, both in cardiovascular, in surgery, and in vision." — Tim Schmid

Oncology Strategy in Multiple Myeloma: Positioning Tecvayli, Talvey and Carvykti; Use of MRD

Sentiment: Positive

"So we start off with the Tech DERA information... This is really community-ready therapy that's proven in unprecedented efficacy rate in the second line plus setting... And then when you bring CARVICTI in, Carvictee is really the most successful CAR T therapy... a single-dose therapy with really a tremendous shot at what we would count as a cure." — John Reed
"Indeed, on MRD, that is exciting for us... we are mindful, however, that it's only an option in the United States... But indeed, we will be speaking with the [FDA] on opportunities to accelerate some of our development... a place where this could be particularly apropos is with our new tri-antibody for myeloma, romantamig." — John Reed

Bull Case

A diversified, increasingly high-growth portfolio in oncology, immunology, neuroscience, and medtech—backed by visible pipeline and mix upgrades—supports accelerating revenue toward double digits with steady margin expansion and multiple $5B+ assets (Tremfya, CAPLYTA, Inlexo, Milvexian) driving upside.

Bear Case

Litigation overhang, policy/tariff headwinds, execution risk in medtech (EP/PFA, Ottava) and new drugs (Inlexo, Milvexian), plus ongoing LOE erosion and only modest guided margin leverage, could prevent J&J from achieving its targeted double-digit growth and constrain valuation re-rating.

Looking Ahead

Investors will be closely watching Johnson & Johnson's next quarterly report for continued execution, particularly around credibility of Double-Digit Revenue Growth Outlook vs. Street’s ~6% Assumptions. With operating margins at 21.9%, margin trends will remain a focal point. The muted stock reaction on earnings day suggests the market is taking a wait-and-see approach, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Johnson & Johnson's revenue in Q4 2025?

Johnson & Johnson reported Q4 2025 revenue of $24.6B, representing a +9.1% year-over-year change.

Did Johnson & Johnson beat earnings expectations in Q4 2025?

The stock moved -0.1% on earnings day, suggesting the results were roughly in line with market expectations. The current bull case centers on: A diversified, increasingly high-growth portfolio in oncology, immunology, neuroscience, and medtech—backed by visible pipeline and mix upgrades—supports accelerating revenue toward double digits with steady margin expansion and multiple $5B+ assets (Tremfya, CAPLYTA, Inlexo, Milvexian) driving upside.

What is the bull case for JNJ stock?

The bull case for JNJ centers on: A diversified, increasingly high-growth portfolio in oncology, immunology, neuroscience, and medtech—backed by visible pipeline and mix upgrades—supports accelerating revenue toward double digits with steady margin expansion and multiple $5B+ assets (Tremfya, CAPLYTA, Inlexo, Milvexian) driving upside.

What is the bear case for JNJ stock?

The bear case for JNJ centers on: Litigation overhang, policy/tariff headwinds, execution risk in medtech (EP/PFA, Ottava) and new drugs (Inlexo, Milvexian), plus ongoing LOE erosion and only modest guided margin leverage, could prevent J&J from achieving its targeted double-digit growth and constrain valuation re-rating.

How has JNJ stock performed since its Q4 2025 earnings?

JNJ moved -0.1% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +11.2% since earnings. Year-to-date, the stock has returned +18.6%.

Browse all 400+ earnings reports →

Learn More

Analyze JNJ in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Johnson & Johnson and 400+ other stocks, explore the full platform.

Open JNJ on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.